Baxter said fourth-quarter continuing operations sales were about $2.75 billion, up 1% on a reported basis and 2% at constant currency rates. The company said the sales exceeded its previously issued guidance.

1. 01

   Baxter said fourth-quarter continuing operations sales were about $2.75 billion, up 1% on a reported basis and 2% at constant currency rates. The company said the sales exceeded its previously issued guidance.

2. 02

   The company said fourth-quarter U.S. GAAP diluted loss per share from continuing operations was ($0.95) and adjusted diluted EPS from continuing operations was $0.58, exceeding its previous guidance of $0.50 to $0.53. It cited special items of $908 million after tax, including the Front Line Care goodwill impairment charge, as factors affecting results.

3. 03

   Baxter said it completed the sale of its Kidney Care business to Carlyle on January 31, 2025, and that net after-tax proceeds of about $3.4 billion exceeded its earlier expectations of $3.15 billion to $3.25 billion. The company said it is allocating the proceeds to debt repayment and set a target net leverage of about 3.0x by the end of 2025.

4. 04

   For 2025, the company guided to full-year continuing operations sales growth of 5% to 6% on a reported basis and adjusted diluted EPS of $2.45 to $2.55. For Q1, it guided to sales growth of 3% to 4% on a reported basis and adjusted EPS of $0.47 to $0.50.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.